Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen sees new Enbrel study show positive results

Amgen sees new Enbrel study show positive results

11th January 2008

Amgen and partners Wyeth have seen their anti-inflammatory drug Enbrel show positive results in a new study investigating its use in patients with Alzheimer’s disease.

The study, carried out by University of California researchers, found that Alzheimer’s symptoms were improved in ten minutes after being injected with Enbrel, reports Bloomberg.

One of the study’s authors Edward Tobinick described Enbrel as having the potential to be a “disease-modifying treatment”.

In 2006, the same researchers found that Alzheimer’s patients had shown “sustained cognitive improvement” after six months of weekly injections.

The researchers suggest that an excess of the inflammation protein TNF-alpha triggers the disorder’s development but this is then blocked by Enbrel.

Amgen spokesperson Sonia Fiorenza downplayed the results, suggesting there was “insufficient scientific data” to support claims that a TNF inhibitor could be used to treat Alzheimer’s.

Michael Lampe, spokesman for Wyeth, confirmed that the concept was “interesting” but that the company was not prepared to discuss early-stage research.

Enbrel was approved in 1998 as the first rheumatoid arthritis drug that was derived from proteins instead of chemicals.

Other such drugs using TNF inhibitors include Johnson & Johnson’s Remicade, Bristol-Myers Squibb’s Orencia and Abbott Laboratories’ Humira.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.